A. A. Matrosova

A. A. Matrosova

Auto-generated profile, based on publicly available information

A. A. Matrosova

Endocrinology Research Centre

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2025 in Diabetes mellitus
Verified
Journal Article
Open access
PDF file
IGIvan Golodnikov
Ivan Golodnikov
EPElizaveta S. Podshivalova
Elizaveta S. Podshivalova
VCVadim Chechekhin
Vadim Chechekhin
AZAnatoliy Zubritskiy
Anatoliy Zubritskiy
AMA. A. Matrosova
A. A. Matrosova
ЯДЯ. В. Дворяньчиков
Я. В. Дворяньчиков
BACKGROUND: Latent autoimmune diabetes in adults (LADA) is considered an intermediate form between type 1 (T1DM) and type 2 diabetes mellitus (T2DM). However, the molecular mechanisms underlying its unique clinical and pathogenetic features remain insufficiently studied. Identifying differentially expressed genes (DEGs) in LADA compared to T1DM is essential for developing more personalized diagnostic and therapeutic approaches.OBJECTIVE: To identify DEGs in peripheral blood mononuclear cells (PBMCs) of patients with LADA compared to those with T1DM, and to evaluate differences in DEGs between these patient groups and healthy volunteers.MATERIALS AND METHODS: The study included 60 participants (23 T1DM patients with disease duration of up to 1 year, 15 LADA patients with disease duration of up to 5 years, and 22 healthy volunteers). The median age of LADA patients was 40 [34; 45] years, and for T1DM patients, 26 [21; 31] years. This was a single-center, cross-sectional observational study. PBMCs were isolated from all participants, and single-cell RNA sequencing (scRNA-seq) was performed. Differential gene expression analysis was conducted using a pseudo-bulk approach (pyDEseq2, p<0.05 adjusted for multiple comparisons, |log2FoldChange| ≥0.5). Statistical analyses employed nonparametric tests (Kruskal–Wallis, Mann–Whitney).RESULTS: In LADA patients, reduced expression of HLA-G, SPARC, and C20orf204 and increased expression of AC002460.2 were observed compared to healthy volunteers (p<0.05) in CD4+ Naive T-cells. In the T1DM group, the most significant differences were identified in CD4+ Central memory T-cells (IFIT1, CASP3, LAMP3, HIST1H2BN). When comparing LADA to T1DM, only one transcript, C20orf204, showed statistically significant differential expression (p<0.05) in CD4+ Naive T-cells.CONCLUSION: The findings indicate that LADA and T1DM share similar molecular patterns, with LADA exhibiting moderate changes in the expression of genes associated with immune regulation and inflammation. The minimal differences between these forms of diabetes highlight their pathogenetic similarity.

11 June 2024 in Clinical and experimental thyroidology
Verified
Journal Article
Open access
PDF file
FAF. M. Abdulkhabirova
F. M. Abdulkhabirova
EBEkaterina Bondarenko
Ekaterina Bondarenko
MFM. I. Fadeeva
M. I. Fadeeva
KKK. A. Komshilova
K. A. Komshilova
LULiliia Urusova
Liliia Urusova
NMNatalia G. Mokrysheva
Natalia G. Mokrysheva
Parathyroid carcinoma (PC) accounts for 0.005% of all malignant neoplasms and is usually associated with an unfavourable prognosis. The greatest diagnostic difficulties arise from the atypical location of thyroid neoplasms. The prevalence of ectopic location of parathyroid gland (PG) ranges from 2 to 43%, while the incidence of this anomaly in patients with primary hyperparathyroidism is 16-30%. This article analyses the difficulties in diagnosing PC with atypical location of the thyroid gland, using two clinical cases as examples, and suggests additional methods for a personalised approach.

10 December 2024 in Pediatria. Journal named after G.N. Speransky
Verified
Journal Article
Closed access
YBYe.V. Bondarenko
Ye.V. Bondarenko
EBE.B. Bricheva
E.B. Bricheva
AAA.YU. Abrosimov
A.YU. Abrosimov
ENE.V. Nagayeva
E.V. Nagayeva
PBP.V. Belousov
P.V. Belousov
NMNatalia G. Mokrysheva
Natalia G. Mokrysheva
Medullary thyroid carcinoma (MTC) is one of the rarest tumors of the neuroendocrine system occurring in childhood. MTC represents approximately 4% to 8% of all thyroid malignancies in children with an incidence of 0.03 per 100,000 pediatric population per annum. As a rule, MCT in childhood is presented as part of hereditary syndromes (MEN2A, MEN2B) whereas the prevalence of the sporadic form has not been sufficiently studied as well as its molecular and genetic features. Authors represent the Russia’s first clinical case of sporadic MTC in a 16 years old child. The girl at the age of 14 y/o was examined by an endocrinologist at the place of residence due to the absence of menarche. According to the results of a comprehensive examination, a mass measuring of up to 27 mm was detected in the left lobe of the thyroid gland. Cytological examination revealed a picture suspicious for C-cell carcinoma. The basal calcitonin level was 2160 pg/ml (with 0 to 4.8 pg/ml as a norm). The patient had then underwent thyroidectomy with central lymphadenectomy as a result of histological and immunohistochemical studies of medullary thyroid carcinoma pT2N0 MxLV0Pn0. According to the results of molecular genetic study of peripheral blood, neither germinal pathogenic nor opportunistic mutations in RET gene were detected. Full-exome sequencing of DNA isolated from tumour tissue revealed as pathogenic/conditional pathogenic mutations RET p.M918T, CHEK2 p. R29X, VRK1 p.H119R and ARSE p. G422R. After 3.5 years of follow-up, the patient had a complete structural and biochemical remission of the disease.

16 June 2026 in Clinical and experimental thyroidology
Verified
Journal Article
Closed access
MRM. V. Reinberg
M. V. Reinberg
KSK. Yu. Slashchuk
K. Yu. Slashchuk
EBEkaterina Bondarenko
Ekaterina Bondarenko
APAnastasiia Pershina-Miliutina
Anastasiia Pershina-Miliutina
AMA. A. Matrosova
A. A. Matrosova
ETEkaterina Troshina
Ekaterina Troshina
BACKGROUND: Among differentiated thyroid carcinoma (DTC) cases, patients classified into the intermediate and high postoperative risk groups for recurrence account for over at least 35% of all cases. However, the optimal management strategy, the clinical utility of radioiodine therapy (RAIT), and the factors determining its efficacy remain insufficiently elucidated. Although the prognostic significance of mutations in BRAF, TERT, TP53, and RAS genes has been well described, their impact on the functional activity of the sodium–iodide symporter (NIS), the degree of cellular differentiation, and the relationship with RAIT responsiveness has not been clearly established. AIM: To assess the relationship between the mutational profile of the primary tumor and clinical outcomes after RAIT in patients with intermediate/high-risk DTC, and to identify candidate genes associated with poor therapeutic response. MATERIALS AND METHODS: Next-generation sequencing (NGS) was performed on DNA extracted from formalin-fixed paraffin-embedded (FFPE) samples of primary DTC tumors (N=28). Clinical and anamnestic data of patients meeting inclusion criteria were retrospectively analyzed. The MEDLINE, Google Scholar, and STRING databases were searched for candidate genes implicated in NIS regulation and poor RAIT response. Of the 68 potential genes, 51 distinct mutations were identified in the analyzed samples. Statistical analysis was conducted to evaluate the correlation between clinical characteristics and molecular profiles using Statistica v.12 software (TIBCO Software Inc., USA). RESULTS: The median follow-up duration was 22.5 [16; 62] months. The median number of somatic variants per patient detected by the targeted sequencing panel was 4.5 [3; 8] (range 1–22). The most frequent variants involved BRAF, PTEN, PIGU, and TG. In the subgroup with unfavorable outcomes, clustering of mutations was observed in BRAF, COL5A1, CTNNB1, DUOX2, AKT1, ALK, ERBB2, GLI1, HORMAD2, IYD, NOTCH3, SLC5A8, SMAD3, and TSHR. The difference in the total number of somatic variants between outcome groups did not reach statistical significance (p=0.755). The presence of distant metastases (M1) emerged as a strong predictor of poor outcome (p<0.001), while coexisting autoimmune thyroiditis had no significant impact (p=0.309). CONCLUSION: The absence of a significant difference in the number of somatic variants between patients with favorable and unfavorable responses (p=0.755), together with the clustering of pathogenic mutations in specific genes in the radioiodine-refractory group, suggests that the activation of specific oncogenic signaling pathways, rather than overall genomic instability, is a key determinant of tumor behavior in this solid tumor type. Resistance or incomplete response to radioiodine therapy may result from the concurrent activation of multiple oncogenic signaling pathways, including MAPK, PI3K/AKT/ mTOR, TSH–TSH receptor, TGF-β/SMAD3, Sonic Hedgehog, and β-catenin/Wnt signaling. Further evaluation of candidate genes implicated in aggressive disease behavior in differentiated thyroid cancer is warranted in larger patient cohorts, with particular emphasis on transcript-level expression analyses.

30 July 2026 in Russian Journal of Archive of Pathology
Verified
Journal Article
Closed access
DLD.D. Lysukhin
D.D. Lysukhin
AVA.V. Varlamov
A.V. Varlamov
AMA.A. Matrosova
A.A. Matrosova
NPNano Pachuashvili
Nano Pachuashvili
AAA.YU. Abrosimov
A.YU. Abrosimov
LULiliia Urusova
Liliia Urusova
Papillary thyroid microcarcinomas (PTMCs) account for about 30% of papillary thyroid cancer cases, and the BRAF V600E mutation is one of the driver mutations in the development of papillary thyroid carcinomas. However, traditional molecular diagnostic methods are time-consuming and costly, highlighting the need for alternative approaches, such as machine learning-based analysis of histopathological images. Objective. To evaluate the feasibility of using a Multiple-Instance Learning (MIL) model to predict BRAF status in PTMC patients based on histopathological whole-slide images without explicit region-of-interest annotation. Material and methods. The study included histopathological scans from surgical specimens of 93 PTMC patients (age range 24—72 years, median 48 years) operated between 01.01.2022 and 01.09.2023. BRAF V600E status was determined by Real-Time PCR. For classification, an MIL model (CLAM) with pretrained feature extractors (CTransPath and Virchow) was used. Model performance was assessed using ROC-AUC with 5-fold cross-validation (10 repeats). Results. The BRAF V600E mutation was detected in 62 patients and absent in 31. The highest ROC-AUC (0.83; 95% CI: 0.61—1.00) was achieved using Virchow features with 20% top-attention region filtering. For CTransPath, ROC-AUC was 0.79 (95% CI: 0.60—0.95) with 5% region filtering. Conclusion. The MIL model shows promise for predicting BRAF status in PTMCs from histopathological images, particularly when using Virchow-derived features.